Valeant’s Parkinson’s Drug Tasmar Requires Less Restrictive Liver Enzyme Monitoring
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling change is based on SGPT/ALT and SGOT/AST elevations being rare as reviewed in more than 40,000 patient years.